Histochemical features of stress-induced aggregates in alpha-synuclein overexpressing cells.
alpha-Synuclein is a major component of intracytoplasmic inclusions including Lewy bodies (LB), Lewy neurites (LN) and glial cytoplasmic inclusions, and plays a key role in neurodegenerative processes in Parkinson's disease (PD) and other synucleinopathies. Although the molecular mechanisms of the disease process still remain to be elucidated, recent studies have suggested that an interaction between reactive oxygen species (ROS) and alpha-synuclein may be closely associated with the initiation and/or the progression of synucleinopathies. In this study, we established human dopaminergic SH-SY5Y cell lines overexpressing wild-type or mutant alpha-synuclein and exposed them to various ROS generators. After the exposure to ROS, alpha-synuclein aggregates were formed in the cytoplasm of these cells, and these were immunopositive for ubiquitin, nitrotyrosine and dityrosine, and positive for thioflavin S staining. Thus, the obtained cytoplasmic aggregates shared many features with inclusion bodies in synucleinopathies. The gamma-tubulin and molecular chaperones coexisted as well, suggesting that the aggregate formation is associated with the intracellular transport along microtubules and may reflect protective responses against neuronal insults. This cellular model not only will be informative for our understanding of the pathophysiological process in synucleinopathies, but also can be applied to the screening of neuroprotective molecules with therapeutic potential.
Matsuzaki
Michiko
M
Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryo-Machi, Aoba, Sendai 980-8574, Japan.
Hasegawa
Takafumi
T
Takeda
Atsushi
A
Kikuchi
Akio
A
Furukawa
Katsutoshi
K
Kato
Yoji
Y
Itoyama
Yasuto
Y
D002449:Cell Aggregation / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D058085:Iron Compounds / Q000494:pharmacology; D009154:Mutation / Q000187:drug effects / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000096:biosynthesis* / Q000235:genetics; D017382:Reactive Oxygen Species / Q000378:metabolism*; D051843:Synucleins; D051844:alpha-Synuclein
D018076:DNA, Complementary; D058085:Iron Compounds; D009419:Nerve Tissue Proteins; D017382:Reactive Oxygen Species; C497604:SNCA protein, human; D051843:Synucleins; D051844:alpha-Synuclein